KPTI - Karyopharm: Selective Inhibiting Nuclear Export For Stellar Cancer Treatment

Never promote someone who hasn't made some bad mistakes, because if you do, you are promoting someone who has never done anything. - Philip Fisher

Karyopharm Therapeutics (NASDAQ:KPTI) is a highly promising cancer medicine innovator. Despite that the stock is trading on a downtrend in this bear market, the company fundamentals are robust. The firm is powering by the sound underlying science of selective nuclear export inhibition that, in and of itself, is a key regulatory approach to stellar cancer management. Its lead molecule, selinexor, is being assessed in multiple conditions. Interestingly, Karyopharm